PE20001053A1 - Derivados de 4,4-biarilpiperidina - Google Patents
Derivados de 4,4-biarilpiperidinaInfo
- Publication number
- PE20001053A1 PE20001053A1 PE1999000898A PE00089899A PE20001053A1 PE 20001053 A1 PE20001053 A1 PE 20001053A1 PE 1999000898 A PE1999000898 A PE 1999000898A PE 00089899 A PE00089899 A PE 00089899A PE 20001053 A1 PE20001053 A1 PE 20001053A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- heteroaryl
- alcoxy
- aril
- biarylpiperidine
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 101100295741 Gallus gallus COR4 gene Proteins 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 102000003840 Opioid Receptors Human genes 0.000 abstract 1
- 108090000137 Opioid Receptors Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004202 respiratory function Effects 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
SE REFIERE A DERIVADOS DE 4,4-BIARILPIPERIDINA DE FORMULA I, DONDE R1, R4, R5 Y R6 SON H, (ALCOXI C0-C8)-(ALQUILO C0-C8), ARIL, ARIL-(ALQUILO C1-C8)-, HETEROARILO, HETEROARIL-(ALQUILO C1-C8), ENTRE OTROS; R2 ES H, ARILO, HETEROARILO, HETEROCICLO, SO2R4, COR4, CONR5R6, COOR4, C(OH)R5R6, ENTRE OTROS; R5 Y R6 JUNTO CON C o N FORMAN UN ANILLO SATURADO DE 3-7 MIEMBROS; R3 ES OH, NHSO2R7, COHR7R8, FLUOR, CONHR7; R7 Y R8 SON H, ALQUILO C1-C4, ALCOXI C1-C4, (ALCOXI C1-C4)-(ALQUILO C1-C4), ENTRE OTROS; Z1 Y Z2 SON H, HALO, ALQUILO C1-C5; CON LA CONDICION QUE NO EXISTEN DOS OXIGENOS DE ANILLO ADYACENTES; NO EXISTEN UN OXIGENO ADYACENTE A UN NITROGENO O AZUFRE EN CUALQUIERA DE LOS RESTOS HETEROCICLO, HETEROARILO. EL COMPUESTO I SE UNE A LOS RECEPTORES OPIOIDES Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS COMO ARTRITIS, PSORIASIS, ASMA, ENFERMEDAD INFLAMATORIA DEL INTESTINO, TRASTORNO DE LA FUNCION RESPIRATORIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9956598P | 1998-09-09 | 1998-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001053A1 true PE20001053A1 (es) | 2000-10-14 |
Family
ID=22275622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000898A PE20001053A1 (es) | 1998-09-09 | 1999-09-07 | Derivados de 4,4-biarilpiperidina |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US6720336B2 (es) |
| EP (1) | EP1112255B1 (es) |
| JP (1) | JP2002524445A (es) |
| KR (1) | KR20010075024A (es) |
| CN (1) | CN1316993A (es) |
| AP (1) | AP2001002088A0 (es) |
| AR (1) | AR022376A1 (es) |
| AT (1) | ATE312819T1 (es) |
| AU (1) | AU749096B2 (es) |
| BG (1) | BG105411A (es) |
| BR (1) | BR9913512A (es) |
| CA (1) | CA2343236C (es) |
| CO (1) | CO5170416A1 (es) |
| CZ (1) | CZ2001850A3 (es) |
| DE (1) | DE69928945T2 (es) |
| EA (1) | EA200100203A1 (es) |
| EE (1) | EE200100145A (es) |
| ES (1) | ES2252960T3 (es) |
| GE (1) | GEP20033025B (es) |
| GT (1) | GT199900146A (es) |
| HK (1) | HK1040396A1 (es) |
| HN (1) | HN1999000149A (es) |
| HR (1) | HRP20010167A2 (es) |
| HU (1) | HUP0103542A3 (es) |
| ID (1) | ID29129A (es) |
| IL (1) | IL141506A0 (es) |
| IS (1) | IS5860A (es) |
| MA (1) | MA26686A1 (es) |
| NO (1) | NO20011183L (es) |
| NZ (1) | NZ509841A (es) |
| OA (1) | OA11648A (es) |
| PA (1) | PA8481301A1 (es) |
| PE (1) | PE20001053A1 (es) |
| PL (1) | PL346648A1 (es) |
| SK (1) | SK3032001A3 (es) |
| SV (1) | SV1999000147A (es) |
| TN (1) | TNSN99169A1 (es) |
| TR (1) | TR200100694T2 (es) |
| WO (1) | WO2000014066A1 (es) |
| YU (1) | YU11501A (es) |
| ZA (1) | ZA200101744B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
| EP1038872A1 (en) * | 1999-02-22 | 2000-09-27 | Pfizer Products Inc. | 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands |
| SE9902765D0 (sv) * | 1999-07-21 | 1999-07-21 | Astra Pharma Prod | Novel compounds |
| US6974824B2 (en) * | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| EP1279666A1 (en) | 2001-07-24 | 2003-01-29 | Pfizer Products Inc. | 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| CA2475767A1 (en) | 2002-02-07 | 2003-08-14 | The Curators Of The University Of Missouri | Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds |
| SE0203302D0 (sv) * | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
| SE0203301D0 (sv) * | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
| AU2003276596B8 (en) | 2002-11-26 | 2009-03-05 | Pfizer Products Inc. | Piperidine compounds useful as PPAR activators |
| BRPI0409133B8 (pt) * | 2003-04-08 | 2021-05-25 | Progenics Pharm Inc | preparações farmacêuticas estavéis compreendendo metilnaltrexona |
| CL2004000754A1 (es) * | 2003-04-11 | 2005-02-25 | Janssen Pharmaceutica Nv | Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central. |
| EP1679069A4 (en) * | 2003-10-21 | 2009-05-13 | Dainippon Sumitomo Pharma Co | NEW PIPERIDINE DERIVATIVE |
| HRP20100675T1 (hr) | 2003-12-23 | 2011-01-31 | Astex Therapeutics Limited | Derivati pirazola kao modulatori protein kinaze |
| EP1584335A3 (en) * | 2004-04-05 | 2006-02-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising a carbinol composition and an opioid |
| US7872023B2 (en) * | 2005-02-17 | 2011-01-18 | Research Triangle Institute | Kappa opioid receptor ligands |
| US8524731B2 (en) * | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| BRPI0608818A2 (pt) * | 2005-03-07 | 2010-01-26 | Univ Chicago | uso de antagonista opióides para atenuação de proliferação e migração de células endoteliais |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| AR057035A1 (es) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| WO2006136823A1 (en) * | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| EP1902032A1 (en) | 2005-06-22 | 2008-03-26 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US8541461B2 (en) | 2005-06-23 | 2013-09-24 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
| DE102005061427A1 (de) * | 2005-12-22 | 2007-06-28 | Grünenthal GmbH | Substituierte Oxadiazol-Derivate |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
| GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| PT2139890E (pt) | 2007-03-29 | 2014-09-03 | Wyeth Llc | Antagonistas do receptor opióide periférico e respectivas utilizações |
| CA2682125C (en) | 2007-03-29 | 2015-06-16 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
| EP2134718A2 (en) | 2007-03-29 | 2009-12-23 | Progenics Pharmaceuticals, Inc. | Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof |
| CA2713568C (en) | 2008-02-06 | 2016-09-20 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
| AU2009225434B2 (en) * | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| CA2676881C (en) * | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| EP2263664A1 (en) * | 2009-05-18 | 2010-12-22 | Nestec S.A. | Opioid receptors stimulating compounds (thymoquinone, Nigella sativa) and food allergy |
| CN110392571B (zh) | 2017-01-17 | 2023-07-04 | 梅比斯发现公司 | 取代的3-二烷基氨基甲基-哌啶-4-基-苯甲酰胺及其制备和使用方法 |
| WO2018169818A1 (en) * | 2017-03-12 | 2018-09-20 | Xiaodong Wang | Polycyclic amines as opioid receptor modulators |
| US11584765B2 (en) | 2017-03-12 | 2023-02-21 | Ecstasy LLC | Polycyclic amines as sigma receptor modulators |
| US10258357B1 (en) * | 2017-10-16 | 2019-04-16 | Michael Bruce Horowitz | Catheter based retrieval device with proximal body having axial freedom of movement |
| CN116897043A (zh) | 2020-07-01 | 2023-10-17 | 艾斯特希有限责任公司 | 用于阿片受体调节的多环胺 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1936452C3 (de) * | 1969-07-17 | 1975-06-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Verfahren zur Herstellung von 4,4-Diphenylpiperidlnen |
| US4016280A (en) | 1969-07-17 | 1977-04-05 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 4,4-Diarylpiperidine compositions and use |
| DE2139085C3 (de) * | 1971-08-04 | 1979-01-18 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Halogenierte 4,4-Diphenyl-piperidine, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
| DE2166997C3 (de) | 1971-08-04 | 1980-03-27 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen |
| DE2139084C3 (de) | 1971-08-04 | 1979-03-01 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen |
| ES2066721B1 (es) * | 1993-05-18 | 1996-02-16 | Ferrer Int | Nuevos compuestos derivados de la piridina 1,4-disustituida. |
| US5434171A (en) * | 1993-12-08 | 1995-07-18 | Eli Lilly And Company | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
| US5994369A (en) * | 1995-04-05 | 1999-11-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders |
| JP2000506904A (ja) | 1996-05-16 | 2000-06-06 | シナプティック・ファーマスーティカル・コーポレーション | ジヒドロピリミジン類およびその使用 |
| CA2255727A1 (en) | 1996-05-31 | 1997-12-04 | Trophix Pharmaceuticals, Inc. | Pharmaceutical for treating of neurological and neuropsychiatric disorders |
-
1999
- 1999-09-01 HN HN1999000149A patent/HN1999000149A/es unknown
- 1999-09-03 GT GT199900146A patent/GT199900146A/es unknown
- 1999-09-06 BR BR9913512-4A patent/BR9913512A/pt not_active IP Right Cessation
- 1999-09-06 HK HK02101744.5A patent/HK1040396A1/zh unknown
- 1999-09-06 NZ NZ509841A patent/NZ509841A/en unknown
- 1999-09-06 EP EP99939576A patent/EP1112255B1/en not_active Expired - Lifetime
- 1999-09-06 EA EA200100203A patent/EA200100203A1/ru unknown
- 1999-09-06 KR KR1020017003088A patent/KR20010075024A/ko not_active Ceased
- 1999-09-06 AT AT99939576T patent/ATE312819T1/de not_active IP Right Cessation
- 1999-09-06 TR TR2001/00694T patent/TR200100694T2/xx unknown
- 1999-09-06 AP APAP/P/2001/002088A patent/AP2001002088A0/en unknown
- 1999-09-06 PL PL99346648A patent/PL346648A1/xx not_active Application Discontinuation
- 1999-09-06 AU AU53837/99A patent/AU749096B2/en not_active Ceased
- 1999-09-06 ID IDW20010549A patent/ID29129A/id unknown
- 1999-09-06 HR HR20010167A patent/HRP20010167A2/hr not_active Application Discontinuation
- 1999-09-06 JP JP2000568825A patent/JP2002524445A/ja active Pending
- 1999-09-06 CZ CZ2001850A patent/CZ2001850A3/cs unknown
- 1999-09-06 DE DE69928945T patent/DE69928945T2/de not_active Expired - Fee Related
- 1999-09-06 IL IL14150699A patent/IL141506A0/xx unknown
- 1999-09-06 CA CA002343236A patent/CA2343236C/en not_active Expired - Fee Related
- 1999-09-06 ES ES99939576T patent/ES2252960T3/es not_active Expired - Lifetime
- 1999-09-06 WO PCT/IB1999/001512 patent/WO2000014066A1/en not_active Ceased
- 1999-09-06 EE EEP200100145A patent/EE200100145A/xx unknown
- 1999-09-06 SK SK303-2001A patent/SK3032001A3/sk unknown
- 1999-09-06 HU HU0103542A patent/HUP0103542A3/hu unknown
- 1999-09-06 OA OA1200100057A patent/OA11648A/en unknown
- 1999-09-06 GE GEAP19995785A patent/GEP20033025B/en unknown
- 1999-09-06 CN CN99810757A patent/CN1316993A/zh active Pending
- 1999-09-07 PE PE1999000898A patent/PE20001053A1/es not_active Application Discontinuation
- 1999-09-07 AR ARP990104494A patent/AR022376A1/es not_active Application Discontinuation
- 1999-09-08 PA PA19998481301A patent/PA8481301A1/es unknown
- 1999-09-08 SV SV1999000147A patent/SV1999000147A/es not_active Application Discontinuation
- 1999-09-08 TN TNTNSN99169A patent/TNSN99169A1/fr unknown
- 1999-09-08 MA MA25759A patent/MA26686A1/fr unknown
- 1999-09-09 CO CO99057228A patent/CO5170416A1/es not_active Application Discontinuation
- 1999-09-16 YU YU11501A patent/YU11501A/sh unknown
-
2001
- 2001-02-23 IS IS5860A patent/IS5860A/is unknown
- 2001-03-01 ZA ZA200101744A patent/ZA200101744B/en unknown
- 2001-03-08 NO NO20011183A patent/NO20011183L/no not_active Application Discontinuation
- 2001-04-04 BG BG105411A patent/BG105411A/bg unknown
- 2001-07-10 US US09/901,825 patent/US6720336B2/en not_active Expired - Fee Related
-
2003
- 2003-12-23 US US10/744,735 patent/US20040138220A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20001053A1 (es) | Derivados de 4,4-biarilpiperidina | |
| PE20001341A1 (es) | Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina | |
| KR890012994A (ko) | 인돌, 벤조푸란, 벤조티오펜-함유 리폭시게나제 억제 화합물 | |
| ES8801209A1 (es) | Un procedimiento para la preparacion de quinolinas 2-sustituidas. | |
| DK36786D0 (da) | Thieno-triazolo-1,4-diazepino-2-carbonsyreamider, deres fremstilling og anvendelse i farmaceutiske sammensaetninger | |
| DK0956855T3 (da) | Immunhæmmende effekter af 8-substituerede xanthin-derivater | |
| PE4896A1 (es) | Derivado de quinazolina | |
| ATE56702T1 (de) | Phenolische thioaether als 5-lipoxygenaseinhibitoren. | |
| ES409335A1 (es) | Procedimiento para la preparacion de isotiociano-benzazo- les. | |
| ECSP920893A (es) | Derivados de 2-imidazolin - 5 onas y 2-imidazolin -5-tionas con propiedades fungicidas | |
| ES2114619T3 (es) | Nuevos analogos de la vitamina d. | |
| AR216846A1 (es) | Procedimiento para el tratamiento de gases que contienen sulfuro de hidrogeno | |
| KR910004591A (ko) | 헤테로 고리 화합물 | |
| BR9810156A (pt) | Mistura fungicida, e, processo para o controle de fungos nocivos | |
| MX9100917A (es) | Composicion farmaceutica que comprende compuestos de difenilo | |
| FR2387989A1 (fr) | Analogues des alcaloides de l'ergot | |
| BG99369A (en) | Derivatives of 2-imidazoline-5-on and 2-imidazoline-5-thion of fungicide activity | |
| SE8305157D0 (sv) | Biologiskt aktiva 2,5-piperazindionderivat, sett for framstellning derav samt farmaceutiska kompositioner innehallande desamma | |
| AR002749A1 (es) | Derivados de estiril bencimidazol y composicion farmaceutica que los comprende. | |
| ES2173435T3 (es) | Derivados condensados de 2,3-benzodiazepinas y su utilizacion como agentes inhibidores de receptores de ampa. | |
| ES474242A1 (es) | Un procedimiento para la produccion de compuestos tricicli- cos. | |
| ES274606A1 (es) | Procedimiento para el tratamiento y la prevenciën de la coccidiosis en las aves de corral y otros animales | |
| MA32429B1 (fr) | Modulateurs des canaux des ions calcium et leurs utilisations | |
| ES2158887T3 (es) | Procedimiento para tratar la prostatitis cronica con 17 beta-n-terc-butilcarbamoil-4-aza-5 alfa-androst-1-en-ona. | |
| KR910000150A (ko) | 대사성 골 질환 치료제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |